NCT01900184View on ClinicalTrials.gov

Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Essential Hypertension

Interventions

DRUG

QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

DRUG

Placebo

Contains magnesium stearate, silica dental type, anhydrous lactose

Trial Locations (1)

92502

Biotrial PARIS, Rueil-Malmaison

All Listed Sponsors

lead

Quantum Genomics SA

INDUSTRY

NCT01900184 - Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects | Biotech Hunter | Biotech Hunter